Transcriptomics-based drug repositioning in a neurocysticercosis rat model identifies putative therapeutic candidates reported to mitigate neuroinflammation and neurodegeneration

Neurocysticercosis is a parasitic infection of the brain caused by the larval stage of a pork tapeworm. It is a leading cause of epilepsy in many parts of the world, particularly in low- and middle-income countries. The condition occurs when a person ingests microscopic eggs, which hatch in the gut and travel through the bloodstream to lodge in the brain, forming cysts. While the parasites themselves can be killed with standard anti-parasitic medication, the treatment often creates a new problem. When the parasite dies, it triggers a fierce inflammatory response from the body's immune system. This swelling and inflammation can damage healthy brain tissue, leading to seizures and long-term neurological issues. Doctors currently use steroids to calm this reaction, but these drugs have serious side effects and do not always prevent permanent harm. The core challenge for researchers is to find a way to stop the parasite without causing the brain to attack itself, or to find a way to calm the brain's reaction so that the treatment can work safely.

To solve this, a team of scientists from Peru, the United States, and Uruguay turned to a rat model of the disease to look at the brain's activity at the molecular level. They did not just look for the parasite; they examined the brain's genetic instructions, known as transcriptomics, to see which genes were turned on or off during different stages of the infection. By reading these genetic signals, the researchers could map out the specific pathways the brain uses to fight the infection and how those pathways change when the parasite is treated. This approach allowed them to move beyond simply observing symptoms and instead understand the underlying biological machinery driving the disease.

The researchers studied the brains of rats at two different times: four months and six months after the infection began. They also looked at a group of rats that received anti-parasitic treatment at the four-month mark and were examined two months later. At the four-month stage, the infected brains showed a massive surge in activity related to the immune system. Thousands of genes were working overtime to recruit immune cells and fight the invader, creating a state of intense inflammation. However, by the six-month mark, this activity had quieted down significantly. The number of active immune genes dropped, and the brain appeared to have entered a more stable, albeit still infected, state. This suggests that the parasite or the host had reached a temporary truce, with the immune response becoming less aggressive over time.

The situation changed dramatically when the rats were treated with medication. In the group that received anti-parasitic drugs, the brain's genetic activity exploded. The number of active genes jumped nearly fifteen times higher than in the untreated rats at the same stage. The treatment killed the parasite, but the dying cysts released materials that triggered a massive, renewed inflammatory response. The brain's genetic code showed a frantic return of immune activity, along with a shutdown of the pathways responsible for normal communication between brain cells. This confirmed the long-held suspicion that treating the infection can temporarily worsen the brain's condition by reigniting the inflammatory fire that damages neural tissue.

Using these detailed genetic maps, the scientists employed a computer-based method to search for existing drugs that could reverse these specific patterns of gene activity. They were looking for medications already approved for other human conditions that might calm the brain's overactive immune response or protect it from the damage caused by inflammation. The analysis identified thirty potential candidates. Among these, five drugs stood out because they are known to reduce neuroinflammation and prevent neurodegeneration, which is the death of brain cells. These candidates included vorinostat, ciclosporin, papaverine, valproic acid, and chlorpromazine.

The study highlights that while these drugs are not new, their potential use for neurocysticercosis is a fresh idea. For instance, vorinostat is currently used to treat a type of blood cancer, and valproic acid is a common treatment for epilepsy and bipolar disorder. The researchers found that these drugs have properties that could theoretically block the harmful inflammatory pathways seen in the infected brains while preserving the brain's ability to function. They also checked whether these drugs could cross the blood-brain barrier, the protective shield that keeps many substances out of the brain. Several of the candidates, such as vorinostat and chlorpromazine, showed a high probability of being able to enter the brain, making them strong contenders for further testing.

However, the authors are careful to state that these findings are a starting point, not a final solution. The study was conducted on a small number of rats, and the results are based on computer simulations and genetic analysis rather than clinical trials in humans. The researchers explicitly note that these drugs have not yet been proven to work for this specific disease in living patients. The work serves as a hypothesis, suggesting that repurposing these existing medications could offer a new way to manage the dangerous inflammation associated with treating neurocysticercosis. The next step, according to the team, is to validate these candidates in larger, more rigorous experiments to see if they can truly protect the brain and improve outcomes for patients suffering from this debilitating condition.